Skip to main content
SpringerLink
Log in

Recent Innovations in the Management of Low-Grade Gliomas

  • NEURO-ONCOLOGY (NEUROPLASMS) (M ROSENFELD, SECTION EDITOR)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Advancement in the understanding of biologic mechanisms of low-grade glioma pathophysiology has allowed the modern era of patient-specific genetic profiling, molecular biology, and neuroimaging to design new methods of surgery, radiation, and chemotherapy in hopes of preventing malignant transformation and improving outcomes. Recent innovations in the understanding of MGMT promoter methylation, IDH1 and IDH2 mutations, temozolomide chemotherapy, vascular monoclonal antibody treatment, use of radiation therapy, choice of antiepileptic drugs, surgical resection, and neuroimaging of low-grade gliomas are reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References and Recommended Reading

  1. Louis DN, Ohgaki H The WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109. Epub 2007 Jul 6.

  2. Michotte A. The revised WHO classification of brain tumors. Acta Neurol Belg. 1996;96(2):85–8.

    Google Scholar 

  3. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.

  4. Gilbert MR, Lang FF. Management of patients with low-grade gliomas. Neurol Clin. 2007; 25(4).

  5. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20(8):2076–84.

    Article  PubMed  Google Scholar 

  6. Hartmann C, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res. 2011;17(13):4588–99.

    Article  PubMed  CAS  Google Scholar 

  7. Hoang-Xuan K, et al. Temozolomide as initial treatment for adults with Low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol. 2004;22(15):3133–8.

    Article  PubMed  CAS  Google Scholar 

  8. Kaloshi G, Benouaich-Ameil A, et al. Temozolomide for low-grade gliomas. Predictive impact of 1p/19q loss on response and outcome. Neurology. 2007;68:1831–6.

    Article  PubMed  CAS  Google Scholar 

  9. Sathornsumetee S, et al. New treatment strategies for malignant glioma. Exp Rev Anticancer Ther. 2006;6:1087–104.

    Article  CAS  Google Scholar 

  10. Turcan S, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012 Feb 15. doi: 10.1038/nature10866

  11. Stockhammer F, Misch M, et al. IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. Seizure. 2012;21(3):194–7.

    Article  PubMed  Google Scholar 

  12. Hai Yan et al. IDH1 and IDH2 Mutations in Gliomas. New England Journal of Medicine. Feb 2009.

  13. Lv S, Teugels E, Sadones J, et al. Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma. Anticancer Res. 2011;31(12):4457–63.

    PubMed  CAS  Google Scholar 

  14. Gozé C, Bezzina C, Gozé E, Rigau V, Maudelonde T, Bauchet L, Duffau H. 1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth. J Neurooncol. 2012.

  15. Fu Y, Zheng S et al Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1α and β-catenin signaling: Possible impact on glioma cell metastasis and chemo-resistance. Int J Biochem Cell Biol. 2012.

  16. Chen J, Xia L, et al. Clinical significance and prognostic value of PAX3 expression in human glioma. J Mol Sci. 2011.

  17. Dmitrenko VV, Kavsan VM, et al. Expression of genes belonging to the IGF-system in glial tumors. Tsitol Genet. 2011;45(5):41–57.

    PubMed  CAS  Google Scholar 

  18. Abhishek C, Liping Y. Detection of 1p19q deletion by real-time comparative quantitative PCR. Biomarker Insights. 2012;7:9–17.

    Google Scholar 

  19. Burger P, et al. Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol. 2001;14(9):842–53.

    Article  PubMed  CAS  Google Scholar 

  20. Los M, Roodhart JML, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. The Oncologist. 2007;12(4):443–50. doi:10.1634/theoncologist.12-4-443. PMID 17470687.

    Article  PubMed  CAS  Google Scholar 

  21. Paez JG, Jänne PA, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500. doi:10.1126/science.1099314. PMID 15118125.

    Article  PubMed  CAS  Google Scholar 

  22. Yan L, Beckman RA. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development. BioTechniques. 2005;39(4):565–8. doi:10.2144/000112043. PMID 16235569.

    Article  PubMed  Google Scholar 

  23. Ishii N, et al. Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are unfavorable prognostic factor. Oncogene. 1999;18(43):5870–8.

    Article  PubMed  CAS  Google Scholar 

  24. Kim YH, et al. Alterations in the RB1 pathway in low-grade diffuse gliomas lacking common genetic alterations. Brain Pathol. 2011;21(6):645–51. doi:10.1111/j.1750-3639.2011.00492.x. Epub 2011 May 30.

    Article  PubMed  CAS  Google Scholar 

  25. Kwak H-J, Kim Y-J, et al. Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas. Oncogene. 2011;30:2433–42. doi:10.1038/onc.2010.620. published online 31 January 2011.

    Article  PubMed  CAS  Google Scholar 

  26. Liu W, Lv G, et al. Downregulation of CDKN2A and suppression of cyclin D1 gene expressions in malignant gliomas. Journal of Experimental & Clinical Cancer Research. 2011;30:76. doi:10.1186/1756-9966-30-76.

    Article  Google Scholar 

  27. McGirt MJ, Chaichana KL, Attenello FJ, Weingart JD, Than K, Burger PC, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery. 2008;63:700–7.

    Article  PubMed  Google Scholar 

  28. Mandonnet E. Mathematical modeling of low-grade glioma. Bull Acad Natl Med. 2011;195(1):23–34. discussion 34–6.

    PubMed  Google Scholar 

  29. Khayal et al. ADC and Fractional Anistropy of newly diagnosed Grade II gliomas. NMR in biomedicine. May 2009.

  30. Henson JW, Gonzalez RG. Neuroimaging in glioma therapy. Expert Rev Neurother. 2004;4(4):665–71.

    Article  PubMed  Google Scholar 

  31. de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology. 2004;63:535–7.

    Article  PubMed  Google Scholar 

  32. Gerstner ER, McNamara MB, Norden AD, Lafrankie D, Wen PY. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol. 2009;94:97–101.

    Article  PubMed  CAS  Google Scholar 

  33. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9:453–61.

    Article  PubMed  Google Scholar 

  34. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudo-progression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26:2192–7.

    Article  PubMed  Google Scholar 

  35. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long term-outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26:1338–45.

    Article  PubMed  Google Scholar 

  36. Duffau. The challenge to remove diffuse low-grade gliomas while preserving brain functions. Acta Neurochir. doi:10.1007/s00701-012-1275-7.

  37. Hirsch L. Seizures in patients undergoing resection of Low-Grade Gliomas. Epilepsy Curr. 2009;9(4):98–100.

    Article  PubMed  Google Scholar 

  38. Peruzzi P, Puente E, Bergese S, Chiocca EA. Intraoperative MRI (ioMRI) in the setting of awake craniotomies for supratentorial glioma resection. Acta Neurochir Suppl. 2011;109:43–8.

    Article  PubMed  Google Scholar 

  39. Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative MRI guidance. Cancer. 2005;103:1227–33.

    Article  PubMed  Google Scholar 

  40. Klein M, Engelberts NH, et al. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol. 2003;54(4):514–20.

    Article  PubMed  Google Scholar 

  41. Chang E, Potts M, et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg. 2008;108(2):227–35.

    Article  PubMed  Google Scholar 

  42. Van Breeman MS. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol. 2009;256(9):1519–26.

    Article  Google Scholar 

  43. Newton HB, Goldlust SA, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol. 2006;78(1):99–102.

    Article  PubMed  CAS  Google Scholar 

  44. Van Nifterik KA, Van den Berg J, Slotman BJ, Lafleur MV, Sminia P, Stalpers LJ. Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation.

  45. Bobustuc GC, Baker CH, et al. Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol. 2010;12(9):917–27.

    Article  PubMed  CAS  Google Scholar 

  46. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54(10):1886–93.

    Article  PubMed  CAS  Google Scholar 

  47. Tremont-Lukats IW, Ratilal BO, et al. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev. 2008;2:CD004424.

    PubMed  Google Scholar 

  48. Sirven JI, Wingerchuk DM, et al. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc. 2004;79(12):1489–94.

    Article  PubMed  Google Scholar 

  49. Karim AB, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996;36(3):549–56.

    Article  PubMed  CAS  Google Scholar 

  50. Van de Bent et. Al Adjuvant PCV improves PFS but not OS in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas. EORTC phase 3 trial. J Clin Oncol. 2006.

  51. Suneja G. Postoperative radiation therapy for low-grade glioma patterns of care between 1998 and 2006. Cancer. 2011. doi:10.1002/cncr.2669.

  52. Karim A, Matt B, Hatlevoli R, et al. A randomized trial of dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys. 1996;36:549–56.

    Article  PubMed  CAS  Google Scholar 

  53. Shaw E, Arusell R, et al. Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group Study. J Clin Oncol. 2002;20:2267–76.

    Article  PubMed  CAS  Google Scholar 

  54. Higuchi I. Treatment of LG oligodendroglial tumors without radiotherapy. Neurology. 2004;63:2384–6.

    Article  PubMed  Google Scholar 

  55. Shaw E, Wang M, Coons S, Final report of RTOG 9802: radiation therapy (RT) versus RT+ procarbazine, CCNU (PCV) vincristine chemotherapy for adult low-grade glioma (LGG). J Clin Oncol. 2008:26.

  56. Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol. 2003;14(12):1722–6.

    Article  PubMed  CAS  Google Scholar 

  57. Kesari S, Schiff D. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res. 2009;15(1):330–7.

    Article  PubMed  CAS  Google Scholar 

  58. Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst). 2007;6(8):1079–99. doi:10.1016/j.dnarep.2007.03.008. PMID 17485253.

    Article  CAS  Google Scholar 

  59. Vogelbaum, et al. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol. 2009;11(2):167–75.

    Article  PubMed  CAS  Google Scholar 

  60. Blonski M, Taillandier L, et al. Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life. Neurooncol. 2012;106(2):353–66.

    Article  CAS  Google Scholar 

  61. Finocchiaro, Gaetano; Pellegatta, Serena. Immunotherapy for glioma: getting closer to the clinical arena? Current Opinion in Neurology Issue. 2011;24(6):641–7.

  62. Cairncross G, Berkey B, Shaw E, et al. A phase 3 trial of chemotherapy plus RT vs. RT alone for mixed and pure anaplastic oligodendroglioma (RTOG 9402): an intergroup trial by the RTOG, NCCTG, SWOG, NCIC, CTG, and ECOG. J Clin Oncol. 2006;80:27–35.

    Google Scholar 

  63. van den Bent MJ, et al. First analysis of EORTC 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005;23(16S):1503. (June 1 Supplement).

  64. Schiff et al. Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas. ECOG E3F05 (RTOG 1072 Endorsed) Opened Sept 2009. Updated Jan 2011.

  65. Vogelbaum and Van De Bent. Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic Glioma: The CATNON Intergroup Trial. EORTC 26053 22054 (RTOG 0834 Endorsed) Opened July 2009. Updated Jan 2011.

  66. Vogelbaum, et al. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol. 2009;11(2):167–75. doi:10.1215/15228517-2008-073.

    Article  PubMed  CAS  Google Scholar 

  67. Fisher. Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High Risk Low-Grade Gliomas. RTOG 0424. Opened 2009. Updated May 2011.

  68. Chang. A Phase III (Phase I Closed) Randomized Study of Radiation Therapy and Temozolomide (IND #60,265) Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma and Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant). Amended Mar 2010.

  69. Van de Bent. Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial. Updated Feb 2011.

  70. Campone and Stupp. Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas. EORTC 16027. Updated Dec 2011.

  71. Raymond, Van De Bent. Open Label phase II study on STI571 (Gleevec) administered as a daily oral treatment in gliomas. EORTC protocol 16011–26013.

  72. Baumert, Stupp. Primary chemotherapy with Temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss. EORTC 22033–26033.

  73. Jaeckle. Phase III Ingergroup study of Radiotherapy vs. Temozolomide alone vs. Radiotherapy with concomitant and adjuvant Temozolomide. RTOG 1071.

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Neurology/Neurosurgery, Wexner Medical Center at The Ohio State University Medical Center, 456 West 10th Avenue, Suite 1200, Columbus, OH, 43210, USA

    Shaheryar Hafeez MD & Robert Cavaliere MD

Authors
  1. Shaheryar Hafeez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Cavaliere MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shaheryar Hafeez MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hafeez, S., Cavaliere, R. Recent Innovations in the Management of Low-Grade Gliomas. Curr Treat Options Neurol 14, 369–380 (2012). https://doi.org/10.1007/s11940-012-0185-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-012-0185-6

Keywords

Search

Navigation